The consensus agreed that the BRAF V600E result (obtained on September 2023) was highly likely to be a false positive because of the following: (1) the same lesion tested later in March 2024 by two different methods did not present the mutation; (2) NGS in July 2022 and March 2024 by two different labs was consistent (i.e., both showed the absence of BRAF V600E and the presence of NRAS G12D); and (3) the presence of an NRAS mutation, which is mutually exclusive in 99.4 percent of melanoma cases. Here, NRAS is linked to melanoma.